Methods: At the National Institute of Cancer of Mexico (INCan), we performed a review of the clinical files with a diagnosis of malignant neoplasm metastatic to the uterine cervix between 1990 and 2009. For a systematic review, we conducted a PubMed search between the years 1970 and 2009 of case reports and series of cases of patients with metastatic

gastric, breast, ovarian and colorectal cancer. We analyzed each report individually and extracted the patients’ SBE-β-CD purchase clinical data from our cases and reports, including the primary tumor, cervical metastases and survival rates.

Results: There were 10 cases of tumors metastatic to the uterine cervix. Metastasis was documented in one- half of the patients during follow up, with two of these cases having the cervix as the only site. We included the following reports in the systematic review: 13 reports of gastric-associated cancer, 30 related to breast cancer, nine with ovarian-associated cancer and 10 related to colorectal cancer.

Conclusions: Metastatic cervical activity is an infrequent event. The prognosis of survival

is poor in the presence of gastric or ovarian cancer and cervical metastases.”
“BACKGROUND: Statin therapy is recommended for children with familial hypercholesterolemia (FH), but most children do not reach treatment targets.

OBJECTIVE: Here we present the design and results at baseline of the ongoing CHARON study, to evaluate the safety and efficacy of rosuvastatin.

METHODS: This study comprises an international 2-year open label, titration-to-goal study in 198 children with heterozygous PH aged 6 to 18 years, with rosuvastatin in a maximum Volasertib cost dose of 10 mg (<10 years of age) or 20 mg (older children). In addition, 64 unaffected siblings were enrolled as controls. The primary efficacy outcome is the

change from baseline in low-density lipoprotein cholesterol, and the secondary outcome is the change in carotid intima-media thickness (c-IMT) in patients with FH compared with their siblings. The primary safety outcomes are growth and sexual maturation; secondary outcomes are the change in other lipoprotein levels and the incidence of adverse events, Elacridar research buy discontinuation rates, and abnormal laboratory values.

RESULTS: At baseline, mean age of patients with FH was 12.1.+/- 3.3 years, 44% were boys, and mean low-density lipoprotein cholesterol levels were 6.1 +/- 1.3 mmol/L (235.9 +/- 48.7 mg/dL). Mean c-IMT was 0.399 mm (95% CI, 0.392-0.406 mm) in children with FE versus 0.377 (95% CI, 0.366-0.388 mm) in unaffected siblings (P = .001).

CONCLUSIONS: At baseline, as expected according to on previous observations, children with FE proved to have a greater c-IMT than their healthy siblings. These differences had already occurred at a very young age, which emphasizes the importance of considering early statin initiation in this high-risk population. (c) 2013 National Lipid Association. All rights reserved.